A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan

Inclusion Criteria: * Signed written informed consent * Male and female patients \> or = 18 years of age with diagnosis of melanoma for which treatment with Normothermic Isolated Limb Infusion (ILI) of melphalan would be appropriate * Measurable disease * Disease site(s) must be distal to the planned site of tourniquet placement * Available for immunohistochemical testing of N-cadherin expression tumor tissue * Adequate performance status and organ function, as evidenced by hematological and biochemical blood testing and ECG Exclusion Criteria: * Receipt of ADH-1 prior to this clinical study (prior melphalan via ILI, is okay) * Stage IV melanoma * Chemotherapy, radiotherapy, or any other investigational drug within 4 weeks before study entry * History of tumors that have shown clinically significant evidence of active bleeding within 12 weeks before study entry * Stroke, major surgery, or other major tissue injury within 4 weeks before study entry * Uncontrolled congestive heart failure, coronary artery disease, or life threatening arrhythmias; myocardial infarction within 12 months; significant electrocardiogram (ECG) abnormalities * Allergic reaction to any therapeutic peptide or to melphalan